IWay Technology launches eight series of detection products, focusing on primary and household medical markets

Publication Time:

2023-05-19 00:00

Source:

We have already deployed products in three major areas of testing demand: cancer screening, chronic disease monitoring, and rapid diagnosis. Some products have already been sold online, and we are currently accelerating the development of offline channels." This was revealed by Ding Jianwen, chairman of Aiwei Technology, at the 2022 annual shareholders' meeting on the afternoon of May 19.

Currently, Aiwei Technology, a national-level specialized and new "small giant" enterprise, is expanding its hospital market while also focusing on primary medical care and home medical markets.

Not long ago, the company's developed Helicobacter pylori antigen detection kit (referred to as the "Helicobacter self-test kit") just received the Medical Device Registration Certificate issued by the National Medical Products Administration.

Just like the familiar new coronavirus antigen detection kit, the Helicobacter self-test kit can also be operated by individual users themselves, with simple and quick sampling, testing, and result interpretation.

Leading advantage in hospital market continues to strengthen

As a pioneering enterprise in the field of automated microscopic examination in China, Aiwei Technology has unique advantages in the clinical application of machine vision technology, and its products are widely used in various medical and health institutions' testing laboratories. Among them, the hospital market is its traditional advantage area.

It is reported that Aiwei Technology's testing instruments have accumulated nearly 15,000 installations in China, covering nearly 6,000 hospitals nationwide, and the market share of many leading products ranks among the top in the industry.

In 2022, affected by objective factors such as the epidemic, the number of patient samples in terminal hospitals decreased, and users' willingness to purchase diagnostic instruments decreased, resulting in a decline in the company's operating performance.

The annual report shows that Aiwei Technology achieved revenue of 197 million yuan in 2022 and net profit attributable to the parent company of 17.973 million yuan. In the first quarter of this year, operating revenue was 40.8987 million yuan, and net profit was 2.1453 million yuan.

However, Aiwei Technology adheres to the sales strategy of using instruments to drive the sales of high-margin reagents and consumables, actively lowering instrument prices, further consolidating the leading position of its core instrument products in the sub-segment, and laying a good foundation for subsequent business expansion.

In addition, Aiwei Technology continues to increase investment in technological research and development and accelerate the introduction of technical talents, achieving good results.

The annual report shows that Aiwei Technology has completed pilot tests and production transfer of multiple products, including the 1+2 and 2+4 urine modular assembly lines and the 563 stool analyzer, further strengthening the advantages of its core products. At the same time, it has made effective progress in the development and application of new products, building a comprehensive automated microscopic examination product matrix covering various clinical specimen testing fields such as urine, stool, gynecology, body fluids, and blood.

Currently, Aiwei Technology's AVE-32 series of reproductive tract secretion analyzers has a much higher degree of automation than similar competing products, with outstanding advantages in the detection rate and recognition rate of pathological components; the AVE-26 series of fully automatic blood cell morphology analyzers targets the industry's demand gap, with broad space for import substitution, and is also expected to help drive future performance growth.

As of the end of 2022, the company has 228 valid patents, including 77 domestic invention patents and 13 foreign invention patents, and the number of patents has long been among the top in the domestic industry.

Layout of primary medical care and home markets

Recently, Aiwei Technology stated on the investor interaction platform that the Helicobacter pylori antigen detection kit (colloidal gold immunochromatographic method) developed by the company has obtained the Medical Device Registration Certificate issued by the National Medical Products Administration. This product has high sensitivity and strong specificity and is easy for individual users to operate.

Ding Jianwen said that the company will establish a dedicated sales team to increase the marketing efforts of products such as the Helicobacter self-test kit for primary medical care and home markets.

In fact, the Helicobacter self-test kit is only one of Aiwei Technology's research and development achievements in the layout of sinking markets.

Currently, Aiwei Technology has launched eight series of lightweight POCT (point-of-care testing) products for primary medical care and home markets, including women's health, scientific pregnancy, childhood diarrhea, early tumor screening, gastrointestinal diseases, urinary system diseases, diabetes, and health checkups, effectively covering the three major testing needs of daily physical examinations, early disease screening, and chronic disease monitoring.

It is understood that the above products have been trial-sold through multiple channels such as some e-commerce platforms, physical pharmacies, clinics, and village health centers, and the market feedback has been good.

In addition, Aiwei Technology is actively developing a primary-level intelligent medical system, intending to apply Internet of Things, artificial intelligence, and big data technologies to the digital construction of basic medical care, further promoting the sinking of high-end medical resources to serve the primary level and helping to accelerate the improvement of the tiered diagnosis and treatment system.

With the continuous increase in development efforts and the continuous improvement of marketing channels, the primary medical care and home markets are expected to provide Aiwei Technology with a vast market space.